Zastosowanie przeciwciał anti-TNFα (infliximab) w leczeniu chorej 
z oftalmopatią tarczycową

Jan Komorowski; Joanna Jankiewicz-Wika; Agnieszka Siejka; Hanna Ławnicka; Anna Kłysik; Roman Goś; Agata Majos; Ludomir Stefańczyk; Henryk Stępień

eISSN: 2719-3209
ISSN: 0023-2157

Klinika Oczna / Acta Ophthalmologica Polonica

Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2007
vol. 109

Send email

Copy url:

abstract:

Case report

Zastosowanie przeciwciał anti-TNFα (infliximab) w leczeniu chorej z oftalmopatią tarczycową

Jan Komorowski

¹

,

Joanna Jankiewicz-Wika

¹

,

Agnieszka Siejka

¹

,

Hanna Ławnicka

²

,

Anna Kłysik

³

,

Roman Goś

³

,

Agata Majos

⁴

,

Ludomir Stefańczyk

⁴

,

Henryk Stępień

²

Department of Clinical Endocrinology , Medical University of Łódź, Poland. Head: Professor Jan Komorowski, MD, PhD
Department of Clinical Immunoendocrinology , Medical University of Łódź, Poland. Head: Professor Henryk Stępień, MD, PhD
Department of Clinical Ophthalmology , Medical University of Łódź, Poland. Head: Professor Roman Goś, MD, PhD
Department of Radiology, Medical University of Łódź, Poland. Head: Professor Ludomir Stefańczyk, MD, PhD

Klinika Oczna 2007, 109 (4): 457-460

Online publish date: 2007/12/20

View full text Get citation

TNFα (tumor necrosis factor alpha) plays a central role in the development of thyroid associated ophthalmopathy (TAO). We describe and document by ophthalmic (CAS and NO SPECS scales) and radiological (MRI) evaluation a positive effect of anti-TNFα antibody (infliximab) administration on active TAO in a 58 years old woman with Graves’ disease. The single dose of infliximab administration resulted in a dramatic reduction of inflammation studies and improvement of visual function as measured by MRI and CAS and NO SPECS scales, without noticeable short-term side effects. A randomized prospective study is needed to determine whether infliximab proves to be sufficiently effective in reducing the inflammatory symptoms of TAO, and whether it can be administered safely for a prolonged period without side effects.

keywords:

Zastosowanie przeciwciał anti-TNFα (infliximab) w leczeniu chorej z oftalmopatią tarczycową

Jan Komorowski 1 , Joanna Jankiewicz-Wika 1 , Agnieszka Siejka 1 , Hanna Ławnicka 2 , Anna Kłysik 3 , Roman Goś 3 , Agata Majos 4 , Ludomir Stefańczyk 4 , Henryk Stępień 2

TNFα, anti-TNFα, Graves’ ophthalmopathy

Jan Komorowski

¹

,

Joanna Jankiewicz-Wika

¹

,

Agnieszka Siejka

¹

,

Hanna Ławnicka

²

,

Anna Kłysik

³

,

Roman Goś

³

,

Agata Majos

⁴

,

Ludomir Stefańczyk

⁴

,

Henryk Stępień

²